Targon Corporation, jointly owned by Cytogen Corporation and Elan Corporation, has entered into a world-wide licence agreement with Elan Pharmaceutical Technologies for Elan's oral once-daily, controlled release formulation of morphine sulphate, known as Morphelan. Elan Pharmaceutical is a division of the Elan group and is Cytogen's strategic partner in the Targon venture. Targon will be responsible for the further clinical development of the Morphelan drug.